Telix Pharmaceuticals Ltd
TLXNext catalyst
68Ga-PSMA-11
Biochemical Recurrence of Malignant Neoplasm of Prostate
Get an email about TLX's next catalysts
Track Telix Pharmaceuticals (TLX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
68Ga-PSMA-11 Phase 3 Est. Readout (BiPASS)
Estimated primary completion for 68Ga-PSMA-11 trial (NCT07052214) in PCA. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
89Zr-TLX250 PET/CT
Clear Cell Renal Cell Carcinoma
68Ga-PSMA-11
Biochemical Recurrence of Malignant Neoplasm of Prostate
177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Prostate Cancer
Zirconium Zr 89 Girentuximab
Clear Cell Renal Cell Carcinoma
177Lu girentuximab
Advanced Cancer
177Lu-DOTA-TLX591
Prostate Cancer
Fluciclovine F18
Prostate Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
89Zr-TLX250 PET/CT | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
68Ga-PSMA-11 | Phase 3 | Biochemical Recurrence of Malignant Neoplasm of Prostate | - | - |
177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC | Phase 2 | Prostate Cancer | - | - |
Zirconium Zr 89 Girentuximab | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
177Lu girentuximab | Phase 2 | Advanced Cancer | - | - |
177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer | - | - |
Fluciclovine F18 | Phase 2 | Prostate Adenocarcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Telix Pharmaceuticals Ltd's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Telix Pharmaceuticals Ltd's (TLX) pipeline across Phase 3, Phase 2. Its lead program is 68Ga-PSMA-11 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Telix Pharmaceuticals Ltd's next FDA catalyst?→
Telix Pharmaceuticals Ltd's (TLX) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TLX biotech catalysts?→
Add TLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Telix Pharmaceuticals Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.